SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
A cartoon of a scientist standing in a laboratory, next to a microscope and flasks
Government
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts
June 30, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA
FDA’s AI Rollout Raises Questions Around Readiness, Legality
June 30, 2025
 · 
6 min read
 · 
Natalia Mesa
Facade of the FDA's office in Maryland
Approvals
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
June 30, 2025
 · 
9 min read
 · 
Tristan Manalac
Themis with sword and scales in cyberspace. Ai regulation, artificial intelligence and law issues concept. Vector illustration.
Legal
Supreme Court Leaves PrEP Drug Coverage Decisions to RFK’s Task Force
June 27, 2025
 · 
2 min read
 · 
Annalee Armstrong